treatment-emergent adverse event

(redirected from treatment emergent adverse event)

treatment-emergent adverse event

An event that first appears during treatment, which was absent before or which worsens relative to the pre-treatment state.
References in periodicals archive ?
One or more treatment emergent adverse event occurred in 99% of patients during induction.
13) We also had two Secondary objectives, first to find out the drug which causes maximum improvement of quality of sleep as measured by the Pittsburgh Sleep Quality Index (PSQI) score and secondly to compare incidence of treatment emergent adverse event in each treatment groups.
The rate of permanent treatment discontinuation in the study due to a treatment emergent adverse event was higher in the Rebif arm (21.
In short-term (six-week) acute bipolar mania trials in combination with lithium or valproate, the most common treatment emergent adverse event associated with Zyprexa and lithium or valproate was dry mouth.
In short-term (three- and four-week) acute bipolar mania trials, the most common treatment emergent adverse event associated with olanzapine was drowsiness.
Trilaciclib was well tolerated, with no Grade 3/4 trilaciclib-related treatment emergent adverse events reported.
The TELECAST study's primary endpoints were the percent change from baseline in u5-HIAA at Week 12 and incidence of treatment emergent adverse events (TEAEs).
Among the patients enrolled at the time of the data cutoff for presentation, ADCT-402 has been reasonably well tolerated with the most common treatment emergent adverse events (TEAEs) being fatigue, neutropenia and thrombocytopenia which have been treated symptomatically and, in some cases, with dose delays, reductions and discontinuation.
The data also showed that the treatment was generally safe and well-tolerated by the trial participants, though all patients reported treatment emergent adverse events, the most common of which was procedure related headache.
UCERIS 9 mg and 6 mg were generally well tolerated and the frequency of treatment emergent adverse events was similar to placebo.
Key secondary endpoints include the pruritus numerical rating scale, the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) electronic diary, and safety measures such as the incidence of treatment emergent adverse events and laboratory abnormalities.
Among all patients enrolled at the time of the data cutoff for presentation and evaluable for safety, the most common treatment emergent adverse events have been related to skin and decreased blood counts.
Full browser ?